Overview
Santero Therapeutics focuses on breaking the cycle of chronic infections, particularly in conditions like non-cystic fibrosis bronchiectasis where bacteria establish persistent colonies resistant to standard treatments. The company discovered a master switch controlling bacterial dormancy (RSH enzymes) and is developing small molecules with bactericidal activity to target these persistent bacteria.
In the news
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.